Knowthestock.com
CTMX - CytomX Therapeutics Inc

Hold

Moderate Growth and Improving
WeakStrong
WeakStrong

46%

based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 30.11%
Operating Income Growth is 232.15%
Net Income Growth is 151.64%
Earnings Per Share (EPS) Growth is 145.0%
Net Margin is 28.19%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.73
Debt Ratio is 0.75
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
CytomX Therapeutics Inc (CTMX) - http://cytomx.com/
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Sean McCarthy
Employees - 157
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.